Paris - Delayed Quote • EUR Poxel S.A. (POXEL.PA) Follow Compare 0.1450 +0.0150 (+11.54%) At close: December 24 at 2:00:04 PM GMT+1 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Availability of Poxel’s 2024 Half-Year Financial Report LYON, France, December 23, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announced the availability of its half-year financial report as of June 30, 2024. Poxel Reports Financial Results for First Half 2024 and Provides an Update on its Financial Position and Outlook LYON, France, December 09, 2024--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces its half-year financial results for the period ended June 30, 2024 and provides an update on its financial situation and outlook, in particular following the Poxel Announces Results from November 28, 2024 Annual General Meeting LYON, France, November 29, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces that it held its Annual General Meeting on November 28, 2024, at 9;00 am CET at the Mercure Lyon Centre Château Perrache Hotel, located at 12 Cours de Verdun- Poxel Announces that its Annual General Meeting Will Be Held on November 28, 2024, at 9 am CET and the Availability of Preparatory Documents LYON, France, November 07, 2024--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today informs its shareholders that the Annual General Meeting (AGM) will be held on November 28, 2024, at the Mercure Lyon Centre Château Perrache Hotel, located at 12 Cour Poxel Reports Cash and Revenue for the Third Quarter and Nine Months 2024 and Provides Corporate Update LYON, France, November 06, 2024--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today provided a corporate update and announced its cash position and revenue for the third quarter and the nine months ended September 30, 2024. Poxel Announces Availability of the 2023 Universal Registration Document LYON, France, October 11, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced that the Universal Registration Document (Document d’Enregistrement Universel) for the year ended December 31, 2023, has been filed with the French market authority (Autorité des Marchés F Poxel SA (STU:7PO) Full Year 2023 Earnings Call Highlights: Strategic Moves and Financial Challenges Poxel SA navigates financial restructuring and strategic partnerships amid increased net losses and reduced cash reserves. Poxel Reports Financial Results for Full Year 2023 and Provides Corporate Update LYON, France, October 03, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (MASH2) and rare metabolic disorders, today announced its results for the year ended December 31, 2023, and provided a corporate update. Poxel Announces its Financial Calendar for 2024 LYON, France, October 01, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its calendar for the publication of financial information for 2024. Poxel Announces Agreement with OrbiMed to Monetize a portion of TWYMEEG® Royalties for USD 50 million LYON, France, September 30, 2024--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces that it entered into a non-dilutive financing agreement with OrbiMed for USD 50 million to monetize a portion of Poxel's future royalties and sales-based payments from TWYMEEG Poxel Reports Revenue for the Second Quarter and First Half 2024 and Provides Corporate Update LYON, France, September 09, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today provided a corporate update and announced its revenue for the second quarter and first half of 2024. Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG® for the Treatment of Type 2 Diabetes in Japan OSAKA, Japan & LYON, France, August 07, 2024--Regulatory News: Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura) and POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announced today topline results obtained from a post-marketing c Poxel Provides an Update on Its Financial Position for the Second Quarter and First Half of 2024 and Announces the Rescheduling of Its Annual General Meeting LYON, France, July 15, 2024--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today publishes its cash position, provides an update on its financial situation for the second quarter and first half of 2024, ending June 30, 2024, reviews its activities on June 30, 2024 and an Poxel Reports Revenue for the First Quarter 2024 and Provides Corporate Update LYON, France, May 16, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today reported its revenue for the quarter ended March 31, 2024 and provided a business update. Poxel Provides a Financial Update for the First Quarter 2024 and Announces the Postponement of its 2023 Full-Year Results Release LYON, France, April 29, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today reported its cash position, provided a financial and business update for the first quarter ended March 31, 2024, and announced the postponement of its 2023 full-year results re Poxel to Report Its 2023 Annual Results by the End of April 2024 LYON, France, March 28, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announces the publication at the end of April 2024 of its 2023 Annual Results, originally scheduled for April 9, 2024, given the expected completion of a transaction by the end of April. Poxel Reports Cash and Revenue for the Full Year 2023 and Provides Corporate Update LYON, France, February 15, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its cash position and revenue and provided a corporate update for the twelve months ended December 31, 2023. Performance Overview Trailing total returns as of 12/24/2024, which may include dividends or other distributions. Benchmark is CAC 40 Return POXEL.PA CAC 40 YTD -73.68% -3.45% 1-Year -75.00% -3.78% 3-Year -97.03% +2.48%